small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search
  • Professionals (401)
  • Capabilities (77)
  • Experience (127)
  • Insights & News (2,126)
  • Other Results (86)

Professionals 401 results

Sandra Edwards
Sandra Edwards
Partner
  • San Francisco
Email
+1 415-591-1412
vCard

Partner

  • San Francisco
Christopher Essig
Christopher Essig
Partner
  • Chicago
Email
+1 312-558-6229
vCard

Partner

  • Chicago
Terry Dee
Terry Dee
Partner
  • Chicago
Email
+1 312-558-8112
vCard

Partner

  • Chicago
View All Professionals

Capabilities 77 results

Practice Area

Product Liability & Mass Torts

Major multinational companies trust Winston to defend their products and reputations in high-profile, high-stakes product liability and mass tort claims. Our Product Liability & Mass Torts Practice is one of the industry’s most seasoned, with a deep bench of experienced lawyers and a unique combination of extensive trial experience and expansive technical knowledge....Read more

Practice Area

Derivatives & Structured Products

Winston represents swap dealers, major swap participants, financial intermediaries, hedge funds, national exchanges, and end-users in a broad array of derivative transactions ranging from highly structured transactions to more traditional trading or hedging transactions, and in regulatory and enforcement issues related to commodities and derivatives....Read more

Industry

Medical Devices

The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Health Care & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions....Read more

Experience 127 results

Experience

|

May 27, 2025

PicoCELA Inc. Closes $1.8 Public Offering

Experience

|

April 11, 2025

Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering

Experience

|

April 3, 2025

Winston Paris advised David Vincent, CEO and Co-Founder of smartTrade Technologies, in connection with the entry of TA Associates, into the company’s capital

View All Experience

Insights & News 2,126 results

Client Alert

|

August 8, 2025

|

5 Min Read

The Recent Expansion of the QSBS Rules Creates New Opportunities for Venture Capital Funds and Their Investors

The One Big Beautiful Bill Act, enacted on July 4, 2025, modernizes and expands the already favorable tax treatment that applies to investments in qualified small business stock (QSBS). These changes benefit venture capital funds that intend to avail themselves of the tax benefits under the QSBS rules by (i) expanding the universe of companies that the funds can invest in, (ii) increasing the amount of gains that their respective investors can receive that are not subject to federal income tax and (iii) providing the funds with more flexibility in terms of timing their exits from these types of investments. The expansion of the QSBS rules under the Act should be a welcome development for venture capital funds and their investors.

Client Alert

|

August 6, 2025

|

4 Min Read

New York’s LLC Transparency Act Goes into Effect January 1, 2026

In December 2024, Winston’s CTA Task Force attorneys began covering a series of judicial actions that affected the enforcement status of the Corporate Transparency Act and its beneficial ownership information reporting rule.
On December 23, 2023, New York Governor Kathy Hochul signed the LLC Transparency Act into law, with a chapter amendment to be approved by the New York State Legislature. The chapter amendment was later approved, and on March 1, 2024, Governor Hochul signed the amended LLC Transparency Act (the Act) into law. The Act takes effect on January 1, 2026 and requires all limited liability companies formed in New York State or qualified to do business in New York State to file a beneficial ownership disclosure or attestation of exemption with the New York Department of State.

News

|

August 4, 2025

|

3 Min Read

Key Takeaways from Winston’s Fifth Annual Health Care & Life Sciences Summit

Winston & Strawn was pleased to host its fifth annual Health Care & Life Sciences Summit. This year’s event brought together clients, colleagues, and industry leaders for an afternoon of insightful discussions, networking, and perspectives on the shifting dynamics across the health care and life sciences sector....Read more
View All Insights & News

Other Results 86 results

Law Glossary

What Are Interchangeable Biological Products?

A biological product is interchangeable if it is biosimilar to the reference product and is expected to produce the same clinical result as the reference product in any given patient. A biosimilar product that is deemed to be interchangeable by the FDA means the biosimilar product can be substituted for the reference product by a pharmacist without consulting the prescriber. The specific requirements for substitution vary by state....Read more

Site Content

What Is General Causation?

In the product liability context, general causation is the legal and scientific determination of whether the product in question has the inherent capability to cause the alleged injury under certain circumstances. Establishment of general causation is a critical aspect of a plaintiff’s case, and typically requires scientific evidence, such as epidemiology or toxicology, and expert testimony to establish a causal connection between the product’s design, manufacturing, or warnings and the injury or injuries at issue. As contrasted to specific causation, the focus in a general causation inquiry is on whether the product or exposure, as a general matter, can cause the type of injury claimed by the plaintiff. A general causation inquiry does not assess any facts unique to a particular plaintiff....Read more

Site Content

What Is a Manufacturing Defect?

In the product liability context, a manufacturing defect claim arises when a plaintiff alleges that a mistake occurred during the manufacturing process of a particular product that made it different from its intended design. Unlike a design defect claim, which concerns the inherent dangers of a product’s design, manufacturing defect claims focus on deviations from the product’s intended specifications....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising